SelectQuote, Inc. Reports Preliminary Second Quarter 2023 Results and Raises Full Year 2023 Guidance
SelectQuote, Inc. (NYSE: SLQT) announced preliminary financial results for Q2 FY2023, estimating revenue between
- Q2 FY2023 revenue expected between $300 million and $320 million.
- Net income for Q2 FY2023 projected at $11 million to $23 million.
- Increased full-year revenue guidance to $890 million to $960 million.
- Reduced full-year net loss forecast from $113 million to $89 million to $98 million to $78 million.
- Adjusted EBITDA for FY2023 guidance improved to $0 to $25 million.
- Projected net loss suggests sustained financial challenges despite improved guidance.
Second Quarter 2023 Preliminary Results
-
Revenue for the second quarter of fiscal year 2023 expected in a range of
to$300 million $320 million -
Net income for the second quarter of fiscal year 2023 expected in a range of
to$11 million $23 million -
Adjusted EBITDA* for the second quarter of fiscal year 2023 expected in a range of
to$45 million $60 million
Guidance for the Full Year 2023
-
Revenue for the full fiscal year 2023 now expected in a range of
to$890 million vs. prior guidance of$960 million to$850 million $950 million -
Net loss for the full fiscal year 2023 now expected in a range of
to$98 million vs. prior guidance of$78 million to$113 million $89 million -
Adjusted EBITDA* for the full fiscal year 2023 now expected in a range of
to$0 vs. prior guidance of$25 million ( to$20) million $10 million
Chief Executive Officer
Forward Looking Statements
This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.
There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: the ultimate duration and impact of the ongoing COVID-19 pandemic and any other public health events, our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, including exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the
Non-GAAP Financial Measures
This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA and cash EBITDA, which are non-GAAP financial measures. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly titled measures presented by other companies. We define Adjusted EBITDA as income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, and certain add-backs for transaction costs and non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. We define cash EBITDA as Adjusted EBITDA excluding the impacts from the estimates of future renewal commission revenue. The most directly comparable GAAP measure for both Adjusted EBITDA and cash EBITDA is net income (loss). We monitor and have presented in this release Adjusted EBITDA and cash EBITDA because they are key measures used by our management and Board of Directors to understand and evaluate our operating performance, to establish budgets and to develop operational goals for managing our business. In particular, we believe that excluding the impacts of certain transactions in calculating Adjusted EBITDA and cash EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.
We believe that these non-GAAP financial measures help identify underlying trends in our business that could otherwise be masked by the effect of the transactions that we exclude in the calculations of these non-GAAP financial measures. Accordingly, we believe that these financial measures provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects.
The following tables present reconciliations of Adjusted EBITDA to net income (loss):
Second quarter 2023 preliminary results |
|||||||
(in thousands) |
Range |
||||||
Net income |
$ |
11,000 |
|
$ |
23,000 |
||
Income tax expense |
|
2,000 |
|
|
7,000 |
||
Interest expense, net |
|
19,000 |
|
|
19,000 |
||
Depreciation and amortization |
|
6,000 |
|
|
6,000 |
||
Share-based compensation expense |
|
3,000 |
|
|
3,000 |
||
Transaction costs |
|
4,000 |
|
|
2,000 |
||
Adjusted EBITDA |
$ |
45,000 |
|
$ |
60,000 |
Fiscal year 2023 guidance |
|||||||||
(in thousands) |
Range |
||||||||
Net loss |
$ |
(98,000 |
) |
|
$ |
(78,000 |
) |
||
Income tax benefit |
|
(28,000 |
) |
|
|
(25,000 |
) |
||
Interest expense, net |
|
74,000 |
|
|
|
74,000 |
|
||
Depreciation and amortization |
|
24,000 |
|
|
|
24,000 |
|
||
Share-based compensation expense |
|
12,000 |
|
|
|
12,000 |
|
||
Transaction costs |
|
16,000 |
|
|
|
18,000 |
|
||
Adjusted EBITDA |
$ |
— |
|
|
$ |
25,000 |
About
Founded in 1985,
With an ecosystem offering high touchpoints for consumers across Insurance, Medicare, Pharmacy, and Value-Based Care, the company now has four core business lines:
*See “Non-GAAP Financial Measures” for additional information regarding the non-GAAP financial measures referenced in this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005374/en/
Investor Relations:
877-678-4083
investorrelations@selectquote.com
Media:
913-286-4931
matt.gunter@selectquote.com
Source:
FAQ
What are SelectQuote's projected revenues for Q2 FY2023?
What is the net income forecast for SelectQuote in Q2 FY2023?
How has SelectQuote adjusted its full-year revenue guidance?
What is the expected net loss for SelectQuote in FY2023?